Letter from the Editor

Home > Neurology > EAN 2019

Read the full Report (pdf)

European Academy of Neurology

29 June – 2 July 2019 Oslo, Norway

Featured articles

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University Düsseldorf, Germany

Conference

EAN 2019

10 February, 2021 16:01

Online First

Alzheimer’s Disease and other Dementias

A necessary shift of focus to the earlier stages of Alzheimer’s

Presented By

Prof. Bart de Strooper, Katholieke Universiteit Leuven, Belgium

Conference

EAN 2019

27 August, 2019 23:51

Biomarkers and how to use them

Conference

EAN 2019

27 August, 2019 22:54

Antipsychotics increase mortality regardless of comorbidity

Presented By

Dr Ane Nørgaard, Rigshospitalet, Denmark

Conference

EAN 2019

27 August, 2019 21:55

PDD and DLB represent two different disorders

Conference

EAN 2019

27 August, 2019 14:57

Epilepsy

Neuroinflammatory pathways as biomarkers and treatment targets

Presented By

Prof. Annamaria Vezzani, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy

Conference

EAN 2019

27 August, 2019 23:59

Panel of inflammation-associated microRNAs as epilepsy biomarker

Conference

EAN 2019

27 August, 2019 22:01

Clinical and cost effectiveness of levetiracetam vs valproate

Trial

SANAD II

Conference

EAN 2019

27 August, 2019 21:02

Long-term effect of recurrent febrile seizures

Presented By

Dr Julie Werenberg Dreier, Aarhus University, Denmark

Conference

EAN 2019

27 August, 2019 15:03

Migraine

The role of neurogenic inflammation in migraine

Presented By

Prof. Lars Edvinsson, Lund University, Sweden

Conference

EAN 2019

27 August, 2019 23:09

Atogepant efficacious, safe, and well-tolerated for migraine prevention

Conference

EAN 2019

27 August, 2019 22:11

Short- and long-term efficacy of erenumab in hard-to-treat patients

Trial

LIBERTY, STRIVE

Conference

EAN 2019

27 August, 2019 21:13

Fremanezumab results of the FOCUS study

Trial

Phase 3, FOCUS

Conference

EAN 2019

27 August, 2019 20:15

Galcanezumab reduces healthcare resource utilisation

Trial

Phase 3, REGAIN

Conference

EAN 2019

27 August, 2019 19:17

Lasmiditan in migraine patients with CV risk factors

Trial

Phase 3, SAMURAI and SPARTAN

Conference

EAN 2019

27 August, 2019 18:18

Factors influencing choice of prophylactic migraine therapy

Trial

PANORAMA

Conference

EAN 2019

27 August, 2019 15:19

Multiple Sclerosis

Treating MS from disease onset

Presented By

Dr Kjell-Morten Myhr, Haukeland University Hospital, Norway

Conference

EAN 2019

27 August, 2019 23:29

Prognostic blood and MRI biomarkers

Trial

EXPAND

Conference

EAN 2019

27 August, 2019 22:31

Long-term effects of established treatments

Trial

CARE-MS I, CLARITY

Conference

EAN 2019

27 August, 2019 21:33

Randomised and observational studies comparing treatments

Presented By

Prof. Giancarlo Comi, Vita-Salute San Raffaele University, Italy

Trial

Phase 3, SUNBEAM and RADIANCE

Conference

EAN 2019

27 August, 2019 20:34

Experimental MS treatments

Trial

MS-SPI; TG1101-RMS201

Conference

EAN 2019

27 August, 2019 19:36

Generalised EBV vaccine for progressive MS well-tolerated

Conference

EAN 2019

27 August, 2019 15:37

Autologous haematopoietic stem cell transplantation

Presented By

Dr Alice Mariottini, Careggi University Hospital, Italy

Trial

Phase 3, MIST

Conference

EAN 2019

27 August, 2019 14:38

Promising results of novel NMOSD treatments

Conference

EAN 2019

27 August, 2019 09:40

Neuromuscular Disorders

AVXS-101 and nusinersen for spinal muscular atrophy type 1

Trial

Phase 1/2, STRONG, ENDEAR, SHINE

Conference

EAN 2019

27 August, 2019 23:43

Ataluren in nonsense mutation Duchenne

Trial

Cohort study, STRIDE, CINRG

Conference

EAN 2019

27 August, 2019 19:44

Motor nerve biopsy for early diagnosis of lower motor neuron syndromes

Conference

EAN 2019

27 August, 2019 09:45

Parkinson's Disease and other Movement Disorders

Inflammation may change the course of Parkinson’s disease

Presented By

Prof. Vidar Gundersen, University of Oslo, Norway

Conference

EAN 2019

27 September, 2019 23:47

No disease-modifying effect of levodopa/carbidopa in Parkinson’s

Conference

EAN 2019

27 August, 2019 22:48

Novel solution of levodopa/carbidopa prodrugs via CSCI

Conference

EAN 2019

27 August, 2019 21:49

Opicapone: follow-up on the BIPARK I and II trials

Presented By

Prof. Joaquim J. Ferreira, Laboratorio de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Portugal

Trial

Phase 3, BIPARK-I and BIPARK-II

Conference

EAN 2019

27 August, 2019 20:50

Epigallocatechin gallate does not modify MSA progression

Presented By

Dr Johannes Levin, Ludwig-Maximilians-University of Munich, Germany

Trial

PROMESA

Conference

EAN 2019

27 August, 2019 10:51

Stroke

Thrombo-inflammation during ischaemia/reperfusion

Presented By

Prof. Guido Stoll, University of Würzburg, Germany

Trial

ACTION, FAMTAIS

Conference

EAN 2019

27 August, 2019 23:52

Haematoma expansion and mortality in intracerebral haemorrhage after OAC

Conference

EAN 2019

27 August, 2019 12:54

Featured articles

CONTENTS

Online First

Alzheimer’s Disease and other Dementias

Epilepsy

Migraine

Multiple Sclerosis

Neuromuscular Disorders

Parkinson's Disease and other Movement Disorders

Stroke